Verily

Verily Life Sciences LLC, an Alphabet company, is at the forefront of precision health, dedicated to making health data useful so that people can enjoy healthier lives. Originally a division of Google X, Verily became an independent subsidiary of Alphabet Inc. in 2015. The company's core mission revolves around generating and applying evidence from a multitude of diverse data sources to develop personalized healthcare solutions. This comprehensive approach integrates research, care, and health financing, leveraging advanced capabilities in data science, artificial intelligence (AI), and cloud-based analytics to drive innovation across the healthcare ecosystem.

Verily develops a wide array of tools, services, and software designed to significantly enhance healthcare outcomes and accelerate the pace of clinical research. Notable innovations include the Verily Study Watch, a device for capturing continuous physiological and environmental data for clinical studies, and collaborations to miniaturize continuous glucose monitoring (CGM) technology. The company is focused on bridging the critical gap between clinical research and practical care delivery. Verily's platform solutions aim to harmonize complex health datasets, making them AI-ready and fit for purpose across various applications in care, research, and public health. By fostering collaborations with leading life sciences companies, medical device manufacturers, and government organizations, Verily utilizes its deep expertise in hardware, software, and clinical science to enable faster development, achieve meaningful advancements, and deploy impactful health solutions at scale. The company's efforts span chronic disease management, clinical trial optimization, and population health initiatives, all with the overarching goal of shifting healthcare from a reactive, one-size-fits-all model to a proactive, personalized, and precise approach.